SCHEMBL21225808

SCHEMBL21225808

O=C1c2ccccc2C(=O)N1CCCCCCc1c[nH]c2ccccc12

nearest known ligand 0.90

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.90
▸ TDP1 Q9NUW8 3/20 0.90
▸ MEN1 O00255 4/20 0.80
▸ KMT2A Q03164 4/20 0.80
▸ NPC1 O15118 2/20 0.80
▸ RAB9A P51151 2/20 0.80
▸ GAA P10253 2/20 0.80
▸ LMNA P02545 3/20 0.66
▸ HTT P42858 1/20 0.66
▸ TP53 P04637 1/20 0.66
▸ SMN1; SMN2 Q16637 1/20 0.62
▸ DRD2 P14416 2/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ HTR1A P08908 2/20 0.55
▸ HTR2A P28223 1/20 0.52
▸ SLC6A4 P31645 1/20 0.52
▸ HTR7 P34969 1/20 0.52
▸ HRH1 P35367 1/20 0.52
▸ DRD3 P35462 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735125 0.89 MAPT (1.00) MAPTTDP1MEN1KMT2ANPC1
SCHEMBL9613799 0.86 MAPT (0.75) MAPTTDP1MEN1KMT2ANPC1
SCHEMBL10429815 0.84 MAPT (0.67) MAPTTDP1MEN1KMT2ANPC1
SCHEMBL14044219 0.84 MAPT (0.69) MAPTTDP1MEN1KMT2ANPC1
SCHEMBL9596924 0.81 MAPT (0.67) MAPTTDP1MEN1KMT2ANPC1
SCHEMBL14017318 0.81 MAPT (0.65) MAPTTDP1MEN1KMT2ANPC1
SCHEMBL7001306 0.81 HTR2A (0.69) MAPTTDP1MEN1KMT2AHTT
SCHEMBL7889427 0.81 HTR2A (0.69) MAPTTDP1MEN1KMT2AHTT
SCHEMBL7004071 0.81 HTR2A (0.69) MAPTTDP1MEN1KMT2AHTT
SCHEMBL10752984 0.80 MAPT (0.74) MAPTTDP1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030901-B2 Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same THE TRUSTEES OF INDIANA UNIVERSITY (US) 2024-07-09 — — US disclosed
US-20230124268-A1 NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME UNIV INDIANA TRUSTEES (US) 2023-04-20 — — US disclosed
US-11584766-B2 Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same THE TRUSTEES OF INDIANA UNIVERSITY (US) 2023-02-21 — — US disclosed
US-20210070784-A1 NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2021-03-11 — — US disclosed
EP-3749306-A2 NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2020-12-16 — — EP disclosed
WO-2019153007-A2 NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME THE BOARO OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2019-08-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070784-A1 NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME NAMPT, NNT, NAPRT MAPT 920/4885TDP1 1708/4885MEN1 1290/4885
US-12030901-B2 Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same NAMPT, NNT, NAPRT MAPT 920/4885TDP1 1708/4885MEN1 1290/4885
US-20230124268-A1 NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME NAMPT, NNT, NAPRT MAPT 920/4885TDP1 1708/4885MEN1 1290/4885
US-11584766-B2 Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same NAMPT, NNT, NAPRT MAPT 920/4885TDP1 1708/4885MEN1 1290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback